Therapy Areas
Starpharma's VIRALEZE SPL7013 > 99.99% effective against the Delta variant of SARS-CoV-2
29 July 2021 -

Biopharmaceutical company Starpharma revealed on Wednesday that the SPL7013 agent in VIRALEZE nasal spray has a strong virucidal effect against the worldwide delta variant of SARS-CoV-2 and reduces its infectivity by> 99.99% after 30 seconds of exposure in laboratory-based virucidal assays.

Based on laboratory studies, SPL7013, the antiviral agent in VIRALEZE , has now been shown to be virucidal against all four coronaviruses SARS-CoV-2: Alpha, Beta, Gamma and Delta. The antiviral effects of SPL7013 cover a broad spectrum and effective against several respiratory viruses including influenza and RSV, as well as its consistent and potent activity against several SARS-CoV-2 variants.

SPL7013's antiviral testing was performed in the lab of virologist Professor Philippe Gallay at the Scripps Research Institute in the US, where previous studies have shown SPL7013's potent antiviral and virucidal activity against several variants of SARS-CoV-2, including those used worldwide Alpha , beta and gamma variants classified as "Variant of Interest".

The VIRALEZE nasal antiviral spray is approved for sale in Europe and India and is available online in certain markets.

In addition, the Delta variant is reported to be about 60% more transmissible than the already highly infectious Alpha variant and is now the most common variant in India and the UK, where it accounts for more than 90% of new cases, concluded the company.



Related Headlines